Antiepileptic effects of silk-polymer based adenosine release in kindled rats
Pharmacotherapy for epilepsy is limited by high incidence of pharmacoresistance and failure to prevent development and progression of epilepsy. Using the rat hippocampal kindling model, we report on the therapeutic potential of novel silk-based polymers engineered to release the anticonvulsant adeno...
Gespeichert in:
Veröffentlicht in: | Experimental neurology 2009-09, Vol.219 (1), p.126-135 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 135 |
---|---|
container_issue | 1 |
container_start_page | 126 |
container_title | Experimental neurology |
container_volume | 219 |
creator | Szybala, Cory Pritchard, Eleanor M. Lusardi, Theresa A. Li, Tianfu Wilz, Andrew Kaplan, David L. Boison, Detlev |
description | Pharmacotherapy for epilepsy is limited by high incidence of pharmacoresistance and failure to prevent development and progression of epilepsy. Using the rat hippocampal kindling model, we report on the therapeutic potential of novel silk-based polymers engineered to release the anticonvulsant adenosine. Polymers were designed to release 1000 ng adenosine per day during a time span of ten days. In the first experiment rats were kindled by hippocampal electrical stimulation until all animals reacted with stage 5 seizures. Adenosine-releasing or control polymers were then implanted into the infrahippocampal fissure ipsilateral to the site of stimulation. Subsequently, only recipients of adenosine-releasing implants were completely protected from generalized seizures over a period of ten days corresponding to the duration of sustained adenosine release. To monitor seizure development in the presence of adenosine, adenosine-releasing or control polymers were implanted prior to kindling. After 30 stimulations – delivered from days 4 to 8 after implantation – control animals had developed convulsive stage 5 seizures, whereas recipients of adenosine-releasing implants were still protected from convulsive seizures. Kindling was resumed after nine days to allow expiration of adenosine release. During additional 30 stimulations, recipients of adenosine-releasing implants gradually resumed kindling development at seizure stages corresponding to those when kindling was initially suspended, while control rats resumed kindling development at convulsive seizure stages. Blockade of adenosine A
1 receptors did not exacerbate seizures in protected animals. We conclude that silk-based adenosine delivery exerts potent anti-ictogenic effects, but might also have at least partial anti-epileptogenic effects. Thus, silk-based adenosine augmentation holds promise for the treatment of epilepsy. |
doi_str_mv | 10.1016/j.expneurol.2009.05.018 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2728789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488609001861</els_id><sourcerecordid>67591638</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-393563e22dd513983cf61087e49320cbb207a5367d923ee1ce2763f40c34ba423</originalsourceid><addsrcrecordid>eNqFkc1u1DAUhS0EotPCK0A2sMtw_RM73iCNqvIjFbGBteU4N-Cpxw52pmrfHpcZDbDqypLvd4-O_RHymsKaApXvtmu8myPucwprBqDX0K2B9k_IioKGlgkOT8kKgIpW9L08I-elbKGCgqnn5IxqIYErtiJfNnHxOPuA8-Jdg9OEbilNmpriw007p3C_w9wMtuDY2BFjKj5ikzFgvWp8bG58HEMdZruUF-TZZEPBl8fzgnz_cPXt8lN7_fXj58vNdes6LpaWa95JjoyNY0e57rmbJIVeodCcgRsGBsp2XKpRM45IHTIl-STAcTFYwfgFeX_InffDDkeHcck2mDn7nc33Jllv_p9E_9P8SLeGKdarXteAt8eAnH7tsSxm54vDEGzEtC9Gqk5TyftHwdqUciZUBdUBdDmVknE6taFgHpyZrTk5Mw_ODHSmOqubr_59zN-9o6QKvDkCtjgbpmyj8-XEMdprSf9U2Bw4rF9_6zGb4jxGh6PP1aoZk3-0zG9DlLp9</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>20713247</pqid></control><display><type>article</type><title>Antiepileptic effects of silk-polymer based adenosine release in kindled rats</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Szybala, Cory ; Pritchard, Eleanor M. ; Lusardi, Theresa A. ; Li, Tianfu ; Wilz, Andrew ; Kaplan, David L. ; Boison, Detlev</creator><creatorcontrib>Szybala, Cory ; Pritchard, Eleanor M. ; Lusardi, Theresa A. ; Li, Tianfu ; Wilz, Andrew ; Kaplan, David L. ; Boison, Detlev</creatorcontrib><description>Pharmacotherapy for epilepsy is limited by high incidence of pharmacoresistance and failure to prevent development and progression of epilepsy. Using the rat hippocampal kindling model, we report on the therapeutic potential of novel silk-based polymers engineered to release the anticonvulsant adenosine. Polymers were designed to release 1000 ng adenosine per day during a time span of ten days. In the first experiment rats were kindled by hippocampal electrical stimulation until all animals reacted with stage 5 seizures. Adenosine-releasing or control polymers were then implanted into the infrahippocampal fissure ipsilateral to the site of stimulation. Subsequently, only recipients of adenosine-releasing implants were completely protected from generalized seizures over a period of ten days corresponding to the duration of sustained adenosine release. To monitor seizure development in the presence of adenosine, adenosine-releasing or control polymers were implanted prior to kindling. After 30 stimulations – delivered from days 4 to 8 after implantation – control animals had developed convulsive stage 5 seizures, whereas recipients of adenosine-releasing implants were still protected from convulsive seizures. Kindling was resumed after nine days to allow expiration of adenosine release. During additional 30 stimulations, recipients of adenosine-releasing implants gradually resumed kindling development at seizure stages corresponding to those when kindling was initially suspended, while control rats resumed kindling development at convulsive seizure stages. Blockade of adenosine A
1 receptors did not exacerbate seizures in protected animals. We conclude that silk-based adenosine delivery exerts potent anti-ictogenic effects, but might also have at least partial anti-epileptogenic effects. Thus, silk-based adenosine augmentation holds promise for the treatment of epilepsy.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2009.05.018</identifier><identifier>PMID: 19460372</identifier><identifier>CODEN: EXNEAC</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Adenosine ; Adenosine - metabolism ; Adenosine - pharmacology ; Adenosine - therapeutic use ; Adenosine A1 Receptor Antagonists ; Animals ; Anticonvulsants - metabolism ; Anticonvulsants - pharmacology ; Anticonvulsants - therapeutic use ; Anticonvulsants. Antiepileptics. Antiparkinson agents ; Biological and medical sciences ; Disease Models, Animal ; Drug Delivery Systems - methods ; Drug Implants - pharmacology ; Electric Stimulation ; Epilepsy ; Epilepsy - drug therapy ; Epilepsy - etiology ; Epilepsy - physiopathology ; Epileptogenesis ; Focal drug delivery ; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy ; Hippocampus - drug effects ; Hippocampus - metabolism ; Hippocampus - physiopathology ; Kindling ; Kindling, Neurologic - drug effects ; Kindling, Neurologic - physiology ; Male ; Medical sciences ; Nervous system (semeiology, syndromes) ; Neurology ; Neuropharmacology ; Pharmacology. Drug treatments ; Polymer ; Polymers - therapeutic use ; Rats ; Rats, Sprague-Dawley ; Receptor, Adenosine A1 - metabolism ; Seizures - drug therapy ; Seizures - etiology ; Seizures - physiopathology ; Silk ; Silk - therapeutic use ; Treatment Outcome</subject><ispartof>Experimental neurology, 2009-09, Vol.219 (1), p.126-135</ispartof><rights>2009 Elsevier Inc.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-393563e22dd513983cf61087e49320cbb207a5367d923ee1ce2763f40c34ba423</citedby><cites>FETCH-LOGICAL-c534t-393563e22dd513983cf61087e49320cbb207a5367d923ee1ce2763f40c34ba423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0014488609001861$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21896147$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19460372$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szybala, Cory</creatorcontrib><creatorcontrib>Pritchard, Eleanor M.</creatorcontrib><creatorcontrib>Lusardi, Theresa A.</creatorcontrib><creatorcontrib>Li, Tianfu</creatorcontrib><creatorcontrib>Wilz, Andrew</creatorcontrib><creatorcontrib>Kaplan, David L.</creatorcontrib><creatorcontrib>Boison, Detlev</creatorcontrib><title>Antiepileptic effects of silk-polymer based adenosine release in kindled rats</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>Pharmacotherapy for epilepsy is limited by high incidence of pharmacoresistance and failure to prevent development and progression of epilepsy. Using the rat hippocampal kindling model, we report on the therapeutic potential of novel silk-based polymers engineered to release the anticonvulsant adenosine. Polymers were designed to release 1000 ng adenosine per day during a time span of ten days. In the first experiment rats were kindled by hippocampal electrical stimulation until all animals reacted with stage 5 seizures. Adenosine-releasing or control polymers were then implanted into the infrahippocampal fissure ipsilateral to the site of stimulation. Subsequently, only recipients of adenosine-releasing implants were completely protected from generalized seizures over a period of ten days corresponding to the duration of sustained adenosine release. To monitor seizure development in the presence of adenosine, adenosine-releasing or control polymers were implanted prior to kindling. After 30 stimulations – delivered from days 4 to 8 after implantation – control animals had developed convulsive stage 5 seizures, whereas recipients of adenosine-releasing implants were still protected from convulsive seizures. Kindling was resumed after nine days to allow expiration of adenosine release. During additional 30 stimulations, recipients of adenosine-releasing implants gradually resumed kindling development at seizure stages corresponding to those when kindling was initially suspended, while control rats resumed kindling development at convulsive seizure stages. Blockade of adenosine A
1 receptors did not exacerbate seizures in protected animals. We conclude that silk-based adenosine delivery exerts potent anti-ictogenic effects, but might also have at least partial anti-epileptogenic effects. Thus, silk-based adenosine augmentation holds promise for the treatment of epilepsy.</description><subject>Adenosine</subject><subject>Adenosine - metabolism</subject><subject>Adenosine - pharmacology</subject><subject>Adenosine - therapeutic use</subject><subject>Adenosine A1 Receptor Antagonists</subject><subject>Animals</subject><subject>Anticonvulsants - metabolism</subject><subject>Anticonvulsants - pharmacology</subject><subject>Anticonvulsants - therapeutic use</subject><subject>Anticonvulsants. Antiepileptics. Antiparkinson agents</subject><subject>Biological and medical sciences</subject><subject>Disease Models, Animal</subject><subject>Drug Delivery Systems - methods</subject><subject>Drug Implants - pharmacology</subject><subject>Electric Stimulation</subject><subject>Epilepsy</subject><subject>Epilepsy - drug therapy</subject><subject>Epilepsy - etiology</subject><subject>Epilepsy - physiopathology</subject><subject>Epileptogenesis</subject><subject>Focal drug delivery</subject><subject>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</subject><subject>Hippocampus - drug effects</subject><subject>Hippocampus - metabolism</subject><subject>Hippocampus - physiopathology</subject><subject>Kindling</subject><subject>Kindling, Neurologic - drug effects</subject><subject>Kindling, Neurologic - physiology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Nervous system (semeiology, syndromes)</subject><subject>Neurology</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Polymer</subject><subject>Polymers - therapeutic use</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Receptor, Adenosine A1 - metabolism</subject><subject>Seizures - drug therapy</subject><subject>Seizures - etiology</subject><subject>Seizures - physiopathology</subject><subject>Silk</subject><subject>Silk - therapeutic use</subject><subject>Treatment Outcome</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1u1DAUhS0EotPCK0A2sMtw_RM73iCNqvIjFbGBteU4N-Cpxw52pmrfHpcZDbDqypLvd4-O_RHymsKaApXvtmu8myPucwprBqDX0K2B9k_IioKGlgkOT8kKgIpW9L08I-elbKGCgqnn5IxqIYErtiJfNnHxOPuA8-Jdg9OEbilNmpriw007p3C_w9wMtuDY2BFjKj5ikzFgvWp8bG58HEMdZruUF-TZZEPBl8fzgnz_cPXt8lN7_fXj58vNdes6LpaWa95JjoyNY0e57rmbJIVeodCcgRsGBsp2XKpRM45IHTIl-STAcTFYwfgFeX_InffDDkeHcck2mDn7nc33Jllv_p9E_9P8SLeGKdarXteAt8eAnH7tsSxm54vDEGzEtC9Gqk5TyftHwdqUciZUBdUBdDmVknE6taFgHpyZrTk5Mw_ODHSmOqubr_59zN-9o6QKvDkCtjgbpmyj8-XEMdprSf9U2Bw4rF9_6zGb4jxGh6PP1aoZk3-0zG9DlLp9</recordid><startdate>20090901</startdate><enddate>20090901</enddate><creator>Szybala, Cory</creator><creator>Pritchard, Eleanor M.</creator><creator>Lusardi, Theresa A.</creator><creator>Li, Tianfu</creator><creator>Wilz, Andrew</creator><creator>Kaplan, David L.</creator><creator>Boison, Detlev</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20090901</creationdate><title>Antiepileptic effects of silk-polymer based adenosine release in kindled rats</title><author>Szybala, Cory ; Pritchard, Eleanor M. ; Lusardi, Theresa A. ; Li, Tianfu ; Wilz, Andrew ; Kaplan, David L. ; Boison, Detlev</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-393563e22dd513983cf61087e49320cbb207a5367d923ee1ce2763f40c34ba423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Adenosine</topic><topic>Adenosine - metabolism</topic><topic>Adenosine - pharmacology</topic><topic>Adenosine - therapeutic use</topic><topic>Adenosine A1 Receptor Antagonists</topic><topic>Animals</topic><topic>Anticonvulsants - metabolism</topic><topic>Anticonvulsants - pharmacology</topic><topic>Anticonvulsants - therapeutic use</topic><topic>Anticonvulsants. Antiepileptics. Antiparkinson agents</topic><topic>Biological and medical sciences</topic><topic>Disease Models, Animal</topic><topic>Drug Delivery Systems - methods</topic><topic>Drug Implants - pharmacology</topic><topic>Electric Stimulation</topic><topic>Epilepsy</topic><topic>Epilepsy - drug therapy</topic><topic>Epilepsy - etiology</topic><topic>Epilepsy - physiopathology</topic><topic>Epileptogenesis</topic><topic>Focal drug delivery</topic><topic>Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy</topic><topic>Hippocampus - drug effects</topic><topic>Hippocampus - metabolism</topic><topic>Hippocampus - physiopathology</topic><topic>Kindling</topic><topic>Kindling, Neurologic - drug effects</topic><topic>Kindling, Neurologic - physiology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Nervous system (semeiology, syndromes)</topic><topic>Neurology</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Polymer</topic><topic>Polymers - therapeutic use</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Receptor, Adenosine A1 - metabolism</topic><topic>Seizures - drug therapy</topic><topic>Seizures - etiology</topic><topic>Seizures - physiopathology</topic><topic>Silk</topic><topic>Silk - therapeutic use</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szybala, Cory</creatorcontrib><creatorcontrib>Pritchard, Eleanor M.</creatorcontrib><creatorcontrib>Lusardi, Theresa A.</creatorcontrib><creatorcontrib>Li, Tianfu</creatorcontrib><creatorcontrib>Wilz, Andrew</creatorcontrib><creatorcontrib>Kaplan, David L.</creatorcontrib><creatorcontrib>Boison, Detlev</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szybala, Cory</au><au>Pritchard, Eleanor M.</au><au>Lusardi, Theresa A.</au><au>Li, Tianfu</au><au>Wilz, Andrew</au><au>Kaplan, David L.</au><au>Boison, Detlev</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antiepileptic effects of silk-polymer based adenosine release in kindled rats</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2009-09-01</date><risdate>2009</risdate><volume>219</volume><issue>1</issue><spage>126</spage><epage>135</epage><pages>126-135</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><coden>EXNEAC</coden><abstract>Pharmacotherapy for epilepsy is limited by high incidence of pharmacoresistance and failure to prevent development and progression of epilepsy. Using the rat hippocampal kindling model, we report on the therapeutic potential of novel silk-based polymers engineered to release the anticonvulsant adenosine. Polymers were designed to release 1000 ng adenosine per day during a time span of ten days. In the first experiment rats were kindled by hippocampal electrical stimulation until all animals reacted with stage 5 seizures. Adenosine-releasing or control polymers were then implanted into the infrahippocampal fissure ipsilateral to the site of stimulation. Subsequently, only recipients of adenosine-releasing implants were completely protected from generalized seizures over a period of ten days corresponding to the duration of sustained adenosine release. To monitor seizure development in the presence of adenosine, adenosine-releasing or control polymers were implanted prior to kindling. After 30 stimulations – delivered from days 4 to 8 after implantation – control animals had developed convulsive stage 5 seizures, whereas recipients of adenosine-releasing implants were still protected from convulsive seizures. Kindling was resumed after nine days to allow expiration of adenosine release. During additional 30 stimulations, recipients of adenosine-releasing implants gradually resumed kindling development at seizure stages corresponding to those when kindling was initially suspended, while control rats resumed kindling development at convulsive seizure stages. Blockade of adenosine A
1 receptors did not exacerbate seizures in protected animals. We conclude that silk-based adenosine delivery exerts potent anti-ictogenic effects, but might also have at least partial anti-epileptogenic effects. Thus, silk-based adenosine augmentation holds promise for the treatment of epilepsy.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>19460372</pmid><doi>10.1016/j.expneurol.2009.05.018</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0014-4886 |
ispartof | Experimental neurology, 2009-09, Vol.219 (1), p.126-135 |
issn | 0014-4886 1090-2430 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2728789 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Adenosine Adenosine - metabolism Adenosine - pharmacology Adenosine - therapeutic use Adenosine A1 Receptor Antagonists Animals Anticonvulsants - metabolism Anticonvulsants - pharmacology Anticonvulsants - therapeutic use Anticonvulsants. Antiepileptics. Antiparkinson agents Biological and medical sciences Disease Models, Animal Drug Delivery Systems - methods Drug Implants - pharmacology Electric Stimulation Epilepsy Epilepsy - drug therapy Epilepsy - etiology Epilepsy - physiopathology Epileptogenesis Focal drug delivery Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy Hippocampus - drug effects Hippocampus - metabolism Hippocampus - physiopathology Kindling Kindling, Neurologic - drug effects Kindling, Neurologic - physiology Male Medical sciences Nervous system (semeiology, syndromes) Neurology Neuropharmacology Pharmacology. Drug treatments Polymer Polymers - therapeutic use Rats Rats, Sprague-Dawley Receptor, Adenosine A1 - metabolism Seizures - drug therapy Seizures - etiology Seizures - physiopathology Silk Silk - therapeutic use Treatment Outcome |
title | Antiepileptic effects of silk-polymer based adenosine release in kindled rats |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A15%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antiepileptic%20effects%20of%20silk-polymer%20based%20adenosine%20release%20in%20kindled%20rats&rft.jtitle=Experimental%20neurology&rft.au=Szybala,%20Cory&rft.date=2009-09-01&rft.volume=219&rft.issue=1&rft.spage=126&rft.epage=135&rft.pages=126-135&rft.issn=0014-4886&rft.eissn=1090-2430&rft.coden=EXNEAC&rft_id=info:doi/10.1016/j.expneurol.2009.05.018&rft_dat=%3Cproquest_pubme%3E67591638%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=20713247&rft_id=info:pmid/19460372&rft_els_id=S0014488609001861&rfr_iscdi=true |